Treatment of Lupus Interstitial Lung Disease with Intravenous Cyclophosphamide

Intravenous pulse cyclophosphamide (IPC) was used to treat lupus interstitial lung disease in 2 patients. Vital capacity increased by 67–110% of baseline values with IPC treatment. Total lung capacity and diffusing capacity also improved. Dyspnea and other manifestations of lupus improved dramatical...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis and rheumatism 1994-03, Vol.37 (3), p.428-431
Main Authors: Eiser, Arnold R., Shanies, Harvey M.
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Cyclophosphamide - administration & dosage
Cyclophosphamide - therapeutic use
Female
Humans
Injections, Intravenous
Lung Diseases, Interstitial - drug therapy
Lung Diseases, Interstitial - etiology
Lung Diseases, Interstitial - physiopathology
Lupus Erythematosus, Systemic - complications
Medical sciences
Pharmacology. Drug treatments
Respiratory Function Tests
Respiratory system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intravenous pulse cyclophosphamide (IPC) was used to treat lupus interstitial lung disease in 2 patients. Vital capacity increased by 67–110% of baseline values with IPC treatment. Total lung capacity and diffusing capacity also improved. Dyspnea and other manifestations of lupus improved dramatically. This is the first report documenting the efficacy of the early use of IPC for acute and chronic interstitial lung disease associated with lupus.
ISSN:0004-3591
1529-0131
DOI:10.1002/art.1780370318